MARK STRICKLAND: Open Payments
NPI 1538110325 · TALLAHASSEE, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,979 in 97 payments from 16 companies in 2025. Trend: 2023 $1,451 · 2024 $1,825 · 2025 $1,979
Food & beverage: $1,979
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $278 |
| Vanda Pharmaceuticals Inc. | 12 | $267 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $235 |
| Otsuka America Pharmaceutical, Inc. | 12 | $172 |
| Teva Pharmaceuticals USA, Inc. | 7 | $167 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $123 |
| Axsome Therapeutics, Inc. | 6 | $123 |
| Almatica Pharma LLC | 6 | $115 |
| E.R. Squibb & Sons, L.L.C. | 5 | $114 |
| Alkermes, Inc. | 6 | $103 |
Products named: VRAYLAR, FANAPT, TRINTELLIX, REXULTI, AUSTEDO XR, CAPLYTA, LOREEV XR, COBENFY.
Industry payments across FL — which companies pay providers there.
